TauRx’s Data Massage Can't Work Out The Kinks Of Failed LMTX Study

28 Jul 2016

• By Maha Elsayed

While the company is hyping the benefit seen in a subgroup analysis of the first Phase III trial of the tau aggregation inhibitor, which failed to show an overall benefit in mild-to-moderate Alzheimer's disease, Datamonitor Healthcare analyst Maha Elsayed raises some questions.

TauRx Pharmaceuticals Ltd. is going to talk to regulators about a route forward for its Alzheimer's disease therapy LMTX, having identified positive results in a subgroup analysis of a pivotal trial that failed overall, but the analysis has limitations and there are questions that could affect the entire field of tau-based interventions in Alzheimer's disease.

TauRx Therapeutics presented the results of the first Phase III study evaluating LMTX’s (leuco-methylthioninium) efficacy and safety in Alzheimer’s disease...